

## Indonesian Black Tea (*Camellia sinensis*) as a Potential Acetylcholinesterase Inhibitor Against Alzheimer's Disease: Docking, DFT, and *In Vitro* Evidence

Mega Safithri<sup>1,2\*</sup>, Rini Kurniasih<sup>3</sup>, Dimas Andrianto<sup>1</sup>, Ukhradiya Magharaniq Safira Purwanto<sup>1</sup>, Muhammad Marsha Azzami Hasibuan<sup>4</sup>, Rini Madyastuti Purwono<sup>5</sup>, Maheswari Alfira Dwicesaria<sup>4</sup>, John G. Acton<sup>6</sup>

<sup>1</sup>Division of Bioanalysis, Department of Biochemistry, Faculty of Mathematics and Natural Science, Institut Pertanian Bogor, Bogor, West Java, 16680, Indonesia

<sup>2</sup>Tropical Biopharmaca Research Center, Institute of Research and Community Services, IPB University, Jalan Taman Kencana No. 3 Kampus IPB Taman Kencana, Bogor 16128, Indonesia.

<sup>3</sup>Division of Biomolecule, Department of Biochemistry, Faculty of Mathematics and Natural Science, Institut Pertanian Bogor, Bogor, West Java, 16680, Indonesia

<sup>4</sup>Department of Biochemistry, Faculty of Mathematics and Natural Science, Institut Pertanian Bogor, Bogor, West Java, 16680, Indonesia

<sup>5</sup>Sub-Division of Pharmacy, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, 16680, Indonesia

<sup>6</sup>School of Biological Sciences, The Flinders University of South Australia. Bedford Park, South Australia, Australia

\*Email: [safithri@apps.ipb.ac.id](mailto:safithri@apps.ipb.ac.id)

### Article Info

Received: Oct 29, 2025

Revised: Nov 1, 2025

Accepted: Dec 16, 2025

Online: Dec 23, 2025

### Citation:

Safithri, M., Kurniasih, R., Andrianto, D., Purwanto, U. M. S., Hasibuan, M. M. A., Purwono, R. M., Dwicesaria, M. A., Acton, J. G. (2025). Indonesian Black Tea (*Camellia sinensis*) as a Potential Acetylcholinesterase Inhibitor Against Alzheimer's Disease: Docking, DFT, and *In Vitro* Evidence. *Jurnal Kimia Valensi*, 11(2), 300-312.

Doi:

[10.15408/jkv.v11i2.47300](https://doi.org/10.15408/jkv.v11i2.47300)

### Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder predominantly affecting the elderly and characterized by dementia. AD pathology involves impaired cholinergic neurotransmission, largely due to  $\beta$ -amyloid ( $A\beta$ ) plaque accumulation, which inhibits choline acetyltransferase (ChAT) and reduces acetylcholine (ACh) levels. Acetylcholinesterase (AChE) contributes to AD progression by hydrolyzing ACh and promoting  $A\beta$  plaque formation, making it a key therapeutic target. This study investigated natural compounds from black tea (*Camellia sinensis*) as potential AChE inhibitors. Molecular docking analyses assessed interactions between bioactive compounds from aqueous black tea extracts and AChE, followed by evaluation of bioavailability, biological activity, toxicity, stability, and reactivity. Epigallocatechin gallate exhibited the strongest binding affinity ( $\Delta G_{bind} = -12.2740$  kcal/mol), forming extensive interactions with the catalytic active site located at the bottom of a deep and narrow gorge (~20 Å). Density Functional Theory (DFT) analysis confirmed its high stability and favorable reactivity in complex with AChE. *In vitro* validation using black tea extracts from Bogor, Indonesia, showed significant AChE inhibition with an  $IC_{50}$  value of  $44.85 \pm 1.48$   $\mu$ g/mL. These findings highlight the promising potential of Indonesian black tea as a natural alternative for Alzheimer's disease therapy.

**Keywords:** Acetylcholinesterase inhibitors, Alzheimer's disease, *Camellia sinensis*, Density Functional Theory, *in vitro*

## 1. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily marked by the aggregation of  $\beta$ -amyloid ( $A\beta$ ) proteins into insoluble plaques within the brain's extracellular matrix<sup>1,2</sup>. Under normal physiological conditions, soluble  $A\beta$

plays beneficial roles in regulating synaptic activity and plasticity, which are essential for learning and memory<sup>3</sup>. The peptide is encoded by exons 16–17 of the *APP* gene on chromosome 21, which produces three major isoforms, APP695, APP751, and APP770, through alternative splicing. APP695, the dominant

isoform in the brain, generates soluble A $\beta$  via  $\beta$ -secretase (BACE1) cleavage through the amyloidogenic pathway<sup>4-6</sup>.

At physiological levels, soluble A $\beta$  contributes to maintaining normal neuronal function<sup>4,5</sup>; however, when present at elevated concentrations, it undergoes aggregation into toxic  $\beta$ -sheet fibrils that form senile plaques, subsequently inhibiting choline acetyltransferase (ChAT), damaging cholinergic neurons, and decreasing acetylcholine levels<sup>6-7</sup>. Additionally, elevated acetylcholinesterase (AChE) activity further aggravates cholinergic dysfunction, and AChE–A $\beta$  complexes accelerate amyloid plaque formation<sup>8</sup>.

Globally, AD affects over 50 million people, with prevalence projected to exceed 115 million by 2050<sup>9</sup>. In Indonesia, dementia cases are expected to rise from 1.2 million in 2016 to 4 million by 2050<sup>10</sup>. Besides genetic predisposition, factors such as poor lifestyle, social isolation, and depression contribute to disease progression<sup>11</sup>. The growing prevalence highlights the need for effective, safe, and affordable therapeutic options.

The first therapeutic approach developed for AD involved inhibiting Alzheimer's amyloidosis using peptide-based or natural compound-based agents derived from various natural sources<sup>3,12,13</sup>. Later, AChE inhibitors became the main therapeutic focus, enhancing cholinergic transmission by preventing acetylcholine hydrolysis<sup>4,14,15</sup>. The FDA-approved inhibitors—tacrine, donepezil, rivastigmine, and galantamine—alleviate symptoms but may cause adverse effects like hepatotoxicity<sup>16-17</sup>, prompting exploration of safer natural alternative therapeutic candidates. This study is important as it provides a potential alternative therapy for Alzheimer's disease by evaluating the bioactivity of black tea, which is considered safer for long-term consumption.

Tea (*Camellia sinensis*), the world's second most consumed beverage, contains neuroprotective compounds<sup>18</sup> such as flavonoids<sup>19</sup>, theaflavins<sup>20-21</sup>, and L-theanine<sup>22</sup>. Black tea, rich in flavonoids and theaflavins formed during fermentation, shows potential as a natural AChE inhibitor<sup>23,24</sup>. However, studies on Indonesian black tea remain limited.

This study investigates the anti-Alzheimer's potential of bioactive compounds from Indonesian black tea through *in silico* molecular docking and *in vitro* AChE inhibition assays to identify safe and effective natural candidates for AD therapy.

## 2. RESEARCH METHODS

The study utilized various laboratory instruments, including glassware, heating and mixing equipment, measuring devices, and a UV-VIS Diode Array Elisa/Microplate Reader SpectroStar Nano

(Serial no. 601-3354), along with a computer equipped with Minitab software for statistical analysis. For the *in silico* analysis, molecular docking was performed using YASARA Structure 19.9.17 (License No. 154638792) on a standard personal computer with sufficient computational resources to carry out the simulations. Discovery Studio 3.5 Client for 2D visualization of ligand–receptor interactions. These tools facilitated molecular modeling and computational interaction analyses essential to the research.

### Materials

The materials used in this study included dried black tea crude material obtained from PT Perkebunan Teh Gunung Mas (Bogor), a research collaborator. This plantation is a certified producer with reliable quality, traceable sourcing, and export distribution extending to the Middle East. Using materials from two distinct highland regions also helps capture natural variation in phytochemical composition. Other materials used were distilled water, and a range of chemical reagents, such as the AChE enzyme assay kit (Abcam ab138871). For the *in silico* study, the 3D structure of donepezil—co-crystallized with the AChE receptor (PDB ID: 6O4W)—was used as the reference ligand. Additionally, 3D structures of natural compounds from black tea, based on secondary data reported by Hasan et al. (2022)<sup>25</sup>, were downloaded from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) in *.sdf* format. The 3D structure of the AChE receptor enzyme was obtained from the Protein Data Bank in *.pdb format*, also under PDB ID: 6O4W.

### Identification of the Active Site of Acetylcholinesterase (AChE, EC 3.1.1.7)

Identifying the receptor's active site is essential for virtual screening, as it guides the evaluation of potential inhibitors. Acetylcholinesterase (AChE, EC 3.1.1.7) was chosen as the receptor. Its active site was identified through homology analysis using BLASTp against the Protein Data Bank (PDB). The AChE sequence (PDB ID: 6O4W) was retrieved and compared with 5–10 homologs. Multiple sequence alignment with Clustal Omega highlighted conserved residues in the active site, based on literature-reported<sup>26</sup>.

### Preparation of Ligand and Receptor Structures for Molecular Docking

This study utilized three ligand types: two reference ligands and test ligands. The reference ligands, donepezil and rivastigmine—both FDA-approved acetylcholinesterase (AChE) inhibitors—were used to validate the grid box and benchmark the effectiveness of test ligands<sup>26</sup>. In addition, donepezil

is the co-crystallized ligand in the crystallographic structure of AChE (PDB ID: 6O4W). The test ligands were natural compounds derived from black tea based on secondary data reported by Hasan et al. (2022)<sup>25</sup>. Their 3D structures were downloaded from PubChem (.*sdf*), energy-minimized using YASARA Structure, and saved in .*pdb* format for virtual screening. The AChE homodimer (PDB ID: 6O4W) was prepared by using only Chain A as the receptor, removing co-crystallized ligands, water molecules, Chain B, and other ligands, and adding hydrogens. The final receptor was saved in .*sce* format. These procedures followed Safithri et al. (2025)<sup>26</sup>.

### Validation of Docking Area (Grid Box) for Virtual Screening

The docking area (grid box) for test ligands was determined based on the optimal redocking position of the co-crystallized ligand, donepezil, on AChE (PDB ID: 6O4W), a critical step for virtual screening. Grid box validation was performed in YASARA Structure using the VINA method via the *dock\_run.mcr* script. The grid was centered on donepezil, with sizes from 2.0 to 7.0 Å (0.5 Å intervals) and validated 100 times. Binding free energy ( $\Delta G_{bind}$ ) was calculated using the AMBER14 force field, and redocking accuracy was assessed by RMSD (< 2.0 Å) between redocked and crystal conformations. The final 3D visualization confirmed positional and conformational accuracy. This procedure followed Safithri et al. (2025)<sup>26</sup>.

### Virtual Screening

Virtual screening was conducted using the best grid box size determined from the validation step. Natural compounds found in black tea were screened and compared with donepezil, a known natural AChE inhibitor<sup>27</sup>. The geometrically optimized test ligands were docked to AChE using the *dock\_runscreening.mcr* script based on the VINA method in YASARA Structure, employing the validated grid box size of 7 Å.

The binding free energy ( $\Delta G_{bind}$ ) between ligands and receptor was calculated using the AMBER14 force field. Each ligand was screened with 100 repetitions, and the best binding pose was selected. The output files included .*txt files* containing  $\Delta G_{bind}$ , dissociation constant ( $K_d$ ), and amino acid residue contact data, as well as .*yob files* containing docking poses.

### Analysis of Virtual Screening Results

Ligand–receptor interactions were visualized in two dimensions using Discovery Studio and in three dimensions using YASARA Structure. Potential inhibitor candidates among the test ligands were analyzed based on  $\Delta G_{bind}$  values, dissociation constants, amino acid residue interactions, and ligand

docking positions relative to the co-crystallized ligand (donepezil) and the reference ligand (rivastigmine).

### Analysis of Biological Activity (PASS), Drug-Likeness, DFT, and Toxicity

Drug-likeness was evaluated using Lipinski's Rule of Five (RO5) via SwissADME (<http://www.swissadme.ch/>) by inputting each compound's canonical SMILES. Biological activity and protein target predictions related to Alzheimer's disease therapy were obtained using PASS Online (<https://www.way2drug.com/passonline/>) and PASS Targets (<https://www.way2drug.com/passtargets/>). Human intestinal absorption (HIA) and blood–brain barrier (BBB) permeability were predicted using ADMETSAR 3.0, while carcinogenicity and toxicity were assessed with Protox 3.0. Quantum chemical calculations followed Neese et al. (2020)<sup>28</sup> using the DFT method (B3LYP-D3MBJ/6-31G) implemented in Orca 6.0.0 to determine HOMO and LUMO energies. These were further used to calculate the HOMO–LUMO gap ( $\Delta E$ ), chemical softness, hardness, global electrophilicity index, and electronegativity.

### Extract Preparation

The sample extraction was conducted using the maceration method. A total of 10 g of simplicia was dissolved in 100 mL of 70% ethanol (1:10). The maceration process was repeated for 24 hours under dark conditions at room temperature. The mixture was then filtered through filter paper, and the residue was re-macerated with fresh solvent until the resulting filtrate no longer exhibited the characteristic color of the sample. All filtrates obtained were pooled and subsequently concentrated using a rotary evaporator at 50 °C until a paste-like extract was formed. The extraction was performed in duplicate, and the extract yield was expressed as a percentage calculated using the equation described by Safithri et al. (2022)<sup>26</sup> and Huda et al. (2022)<sup>29</sup>, resulting in an average yield of  $37.014 \pm 0.298\%$  (equation 1).

$$\text{Extract yeild (\%)} = \frac{\text{Weight of extract obtained (g)}}{\text{Weight of simplicia sample (g)}} \times 100 \dots\dots(1)$$

### Acetylcholinesterase (AChE) Enzyme Inhibition Assay (Abcam: ab138871)

The assay involved three types of solutions: sample, blank, and positive control. All solutions were incubated in the dark for 30 minutes before spectrophotometric analysis at 408 nm. The standard curve was prepared by combining 50  $\mu\text{L}$  of ddH<sub>2</sub>O, 50  $\mu\text{L}$  of AChE solution, and 50  $\mu\text{L}$  of ATCh mix. The ATCh mix contained acetylthiocholine (ATCh) as a synthetic substrate, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman's reagent) as a colorimetric indicator, and assay buffer.

AChE solutions were prepared in a concentration series: 500, 300, 150, 125, 100, 75, 50, 30, 10, 3, 1, and 0 mU/mL. These standards were also incubated in the dark for 30 minutes before spectrophotometric measurement at 408 nm. Acetylthiocholine is hydrolyzed by acetylcholinesterase to produce thiocholine containing a free thiol (-SH) group, which reacts with DTNB to form a yellow product, TNB<sup>2-</sup> (5-thio-2-nitrobenzoic acid), that absorbs light at 408–412 nm. The intensity of the yellow color (measured at 408–412 nm) corresponds to AChE activity. The standard curve was constructed by plotting absorbance values against enzyme concentrations and used to determine enzyme activity in unknown samples or black tea water extracts in this study.

The percentage of acetylcholinesterase (AChE) inhibition was calculated using the equation (2).

$$\% \text{Inhibition} = \left( \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \right) \times 100 \dots \dots (2)$$

where  $A_{\text{control}}$  represents the absorbance of the reaction mixture without the inhibitor, and  $A_{\text{sample}}$  is the absorbance obtained in the presence of the extract or the reference inhibitor. All measurements were performed in duplicate. The black tea extract was tested at concentrations of 0.1, 1, 5, 10, 20, 30, 40, and 50  $\mu\text{g/mL}$ . Donepezil HCl, used as the standard AChE inhibitor, was evaluated at concentrations of 0.00625, 0.0125, 0.025, 0.05, 0.1, and 0.2  $\mu\text{g/mL}$ .


The inhibition values were plotted against the logarithm of the concentration, and the half-maximal inhibitory concentration ( $\text{IC}_{50}$ ) was determined using a four-parameter logistic (4PL) non-linear regression model<sup>23</sup>.  $\text{IC}_{50}$  values for both the extract and Donepezil HCl are reported as mean  $\pm$  standard deviation (SD) based on duplicate measurements.

### 3. RESULTS AND DISCUSSION


#### Structural Characteristics of Acetylcholinesterase (AChE; 6O4W) and Grid Box Validation for Molecular Docking

Acetylcholinesterase (AChE; PDB ID: 6O4W) is a homodimeric enzyme linked by six hydrogen bonds, forming a quaternary structure<sup>27,30</sup>. Its active site is located  $\sim 20 \text{ \AA}$  beneath the surface and consists of the catalytic triad Ser203, His447, and Glu334 (Figure 1). The active-site gorge contains functionally important regions, including the peripheral anionic site (PAS), acyl binding pocket, oxyanion hole, and anionic subsite. PAS residues (Tyr72, Asp74, Tyr124, Ser125, Trp286, Tyr337, Tyr341) guide acetylcholine into the gorge and interact with amyloid- $\beta$ , linking AChE activity to Alzheimer's disease (AD) pathology. The acyl binding pocket (Trp236, Phe295, Phe297, Phe338) near Ser203 accommodates the acetyl group, facilitating tetrahedral intermediate formation and product release, while the oxyanion hole (Gly121, Gly122, Ala204) and anionic subsite (Trp86, Tyr133, Glu202, Gly448, Ile451) stabilize transition states and maintain substrate orientation and catalytic efficiency<sup>31-33</sup>.

The optimal grid box for molecular docking was determined based on  $\Delta G_{\text{bind}}$ , RMSD, and ligand-receptor interaction similarity between re-docked and co-crystallized donepezil. All grid box sizes produced poses highly similar to the native ligand (RMSD 0.0011–0.0019  $\text{\AA}$ ), with the 7  $\text{\AA}$  box selected for its larger volume and consistent interaction patterns<sup>27</sup> ( $\Delta G_{\text{bind}} = -12.3500 \text{ kcal/mol}$ ; RMSD = 0.0011  $\text{\AA}$ ; Figure 2).



**Figure 1.** Active “gorge” site and other key residues of AChE (6O4W)<sup>34-35</sup>. (A) Active and functional regions shown in cartoon form; (B) Front view; (C) Top view; (D) Schematic representation of the AChE active gorge<sup>34</sup>. Green: acyl binding pocket; brown: peripheral anionic site (PAS); orange: anion subsite; cyan: oxyanion hole; magenta: active or catalytic site.



**Figure 2.** Re-docking of the native inhibitor (donepezil) against AChE during grid box validation. (A) Result using AutoDock Vina; (B) Result using YASARA Structure. Red ball-and-stick: native donepezil; yellow ball-and-stick: re-docked donepezil.

### Evaluation of Selected Compounds Following Docking

Virtual screening of 20 bioactive compounds obtained from secondary data reported by Hasan et al. (2022)<sup>25</sup>, identified several potential acetylcholinesterase (AChE; PDB ID: 6O4W) inhibitors using YASARA Structure. Donepezil exhibited a  $\Delta G_{bind}$  of  $-12.350$  kcal/mol, while test ligands ranged from  $-5.981$  kcal/mol (L-theanine) to  $-12.274$  kcal/mol (Epigallocatechin gallate, EGCG). Lower  $\Delta G_{bind}$  values indicate stronger receptor binding<sup>35-37</sup>. EGCG showed the closest  $\Delta G_{bind}$  to donepezil, followed by Chlorogenic Acid ( $-10.858$  kcal/mol), Theaflavin ( $-10.544$  kcal/mol), Theaflavin-3-O-gallate ( $-10.892$  kcal/mol), and Theaflavin-3-gallate ( $-10.857$  kcal/mol). These results align with prior findings that catechins and theaflavins constitute the predominant polyphenols in black tea<sup>38</sup>. The strong *in silico* affinity observed in this study is consistent with previously reported AChE inhibitory activities, where EGCG, theaflavin, and theaflavin-3-gallate exhibited  $IC_{50}$  values of  $30.99 \pm 1.5$   $\mu\text{g/mL}$ ,  $16.64 \pm 0.4$   $\mu\text{g/mL}$ , and  $2.38 \pm 0.08$   $\mu\text{g/mL}$ , respectively<sup>23</sup>.

EGCG exhibited the most potent inhibitory potential, forming eight hydrogen bonds with critical residues including Tyr72, Asp74, Ser125 (Peripheral Anionic Site), Trp86 (anion subsite), Trp286 (PAS), and Gly122 (oxyanion hole). It also engaged in multiple hydrophobic interactions,  $\pi$ - $\pi$  stacking,  $\pi$ - $\pi$  T-shaped contacts, and Van der Waals interactions with His447 and the acyl-binding pocket (**Figure 3; Table 1**), stabilizing the complex and potentially

hindering acetylcholine access. Donepezil and rivastigmine (**Figure 4**), in contrast, formed only a single hydrogen bond with a critical residue, including Tyr124 and Phe295.

Other top ligands—Chlorogenic Acid, Theaflavin, Theaflavin-3-O-gallate, and Theaflavin-3-gallate—also showed favorable binding. Theaflavin-3-O-gallate formed four hydrogen bonds, including Phe295 (acyl binding pocket), supported by  $\pi$ - $\pi$  interactions (**Table 1**). Chlorogenic Acid established nine hydrogen bonds, including with Gly121, Gly122 (oxyanion hole), and Ser203 (active site). Theaflavin-3-gallate formed six hydrogen bonds with PAS residues, while Theaflavin formed only two. According to Luo et al. (2024)<sup>39</sup>, thearubigins, theaflavins, and its derivatives are the major polyphenols in black tea<sup>40,41</sup>, formed during enzymatic fermentation catalyzed by polyphenol oxidase and peroxidase—processes absent in green tea. This oxidation converts catechins into benzotropolone-based dimers, producing theaflavins and thearubigins<sup>39,42</sup>. Among these, theaflavins contribute most to black tea's color, flavor, and bioactivity, including antioxidant, anti-inflammatory, and neuroprotective effects<sup>41,43-46</sup>.

Overall, EGCG displayed the broadest interaction network spanning both catalytic and peripheral sites, with binding affinity comparable to Donepezil and exceeding Rivastigmine. Tea polyphenols are generally divided into (-)-epigallocatechin gallate (EGCG), (-)-epicatechin gallate (ECG), (-)-epigallocatechin (EGC), and (-)-

epicatechin (EC) <sup>45</sup>. EGCG, a polyphenol from the flavan-3-ols subclass, is abundant in green tea but present in smaller amounts in black tea <sup>42</sup> and exhibits antioxidant <sup>47</sup>, anti-inflammatory <sup>48</sup>, and neuroprotective properties <sup>49-50</sup>.

The extensive phenolic hydroxyl groups of EGCG enable multiple hydrogen bonds, hydrophobic,

and Van der Waals interactions, stabilizing the AChE complex and supporting its neuroprotective potential. These findings align with prior studies demonstrating EGCG's ability to prevent amyloid aggregation and remodel misfolded proteins <sup>49,50</sup>, highlighting its promise as a natural anti-Alzheimer's agent.

**Table 1.**  $\Delta G_{bind}$ , Dissociation constant, and interactions of selected ligands against AChE (PDB: 6O4W)

Compound	$\Delta G_{bind}$ (kcal/mol)	Dissociation constant ( $\mu$ M)	Total of H-Bond	H-bond (length in Å)	Hydrophobic & other Interactions
Donepezil (Native ligand/Co-crystall ligand)	-12,350	0,885	2	Phe295 (1,91), Ser293 (2,99)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked : His447, Trp286</li> <li>• Pi-Sigma : Phe338, Tyr341</li> <li>• Pi-Cation : Trp86, Tyr337</li> <li>• VdW : Tyr72, Tyr124, Glu202, Ser203, Leu289</li> </ul>
Rivastigmine (reference ligand)	-8,055	1246	1	Tyr124 (2,13)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked &amp; Pi-Pi T-Shaped : Tyr337, Phe338</li> <li>• Pi-Alkyl : Trp86, His447, Trp286, Phe297, Tyr341</li> <li>• VdW : Asp74, Gly121, Glu202, Ser203, Ala204, Phe295, Arg296</li> </ul>
Epigallocatechin gallate	-12,274	1	8	Tyr72 (3,00), Asp74 (2,60), Trp86 (1,77), Gly122 (2,26), Gly126 (3,02), Ser125 (2,23), Trp286 (2,91, 3,29)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked : Tyr341, Tyr124, Trp86, Trp286</li> <li>• Pi-Pi T-Shaped : Tyr341, Tyr337, Phe338</li> <li>• VdW : Gln71, Gly121, Leu130, Phe295, Phe297, His447</li> <li>• Unfavorable Acceptor-Acceptor : Asn87</li> </ul>
Theaflavin-3-O-gallate	-10,892	10	4	Val294 (2,49), Phe295 (2,44), Arg296 (2,34), Gly342 (2,92)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked : Tyr72, Trp286</li> <li>• Pi-Pi T-Shaped : Trp286</li> <li>• Alkyl &amp; Pi-Alkyl: Leu76</li> <li>• Unfavorable Donor-Donor (&amp; Acceptor-Acceptor) : Glu292</li> </ul>
Chlorogenic Acid	-10,858	11	7	Gly121 (2,58), Gly122 (2,86), Tyr124 (2,66; 2,88), Ser203 (2,71, 2,59), Ser293 (2,15, 2,83), Arg296 (2,18)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked : Trp286</li> <li>• Pi-Alkyl : Phe338</li> <li>• VdW: Gly120, Val294, Leu289, Phe297, Phe295, Tyr341</li> </ul>
Theaflavin-3-gallate	-10,857	11	6	Tyr72 (2,39), Tyr124 (2,04), Gln291 (2,34), Ser293 (2,48), Val294 (2,36), Tyr341 (2,49)	<ul style="list-style-type: none"> <li>• Pi-Pi Stacked : Trp286</li> <li>• Pi-Alkyl : Leu76, Leu289</li> <li>• VdW : Asp74, Phe295, Phe297</li> </ul>




Figure 3. 2D and 3D visualization of Epigallocatechin gallate docking with AChE (6O4W).




Figure 4. 2D and 3D visualization of Rivastigmine (reference ligand) docking with AChE (6O4W).

### PASS, Druglikeness, Carcinogenicity, Toxicity, and Quantum Mechanical Properties

The inhibitory potential of black tea compounds against acetylcholinesterase (AChE; PDB ID: 6O4W) was evaluated using molecular docking, PASS Online, and PASS Target analyses. These structure–activity relationship (SAR)-based models showed high predictive reliability (>95%)<sup>48</sup>. Reference ligands donepezil and rivastigmine validated the system, with donepezil showing the highest probability of activity ( $P_a = 0.788$ ) as a cholinergic AChE inhibitor, while rivastigmine exhibited a lower  $P_a$  value (0.227).

Epigallocatechin gallate (EGCG) emerged as a promising  $\beta$ -amyloid antagonist ( $P_a = 0.436$ ) among the ligands selected through molecular docking, interacting with calcium channels and amyloid precursor-binding proteins. Theaflavin-3-O-gallate and theaflavin-3-gallate exhibited the highest  $P_a$  value (0.584) as amyloid aggregation inhibitors, whereas chlorogenic acid was predicted as a dementia-modulating compound ( $P_a = 0.258$ ). PASS analysis


confirmed that all four compounds had anti-Alzheimer’s potential ( $P_a = 0.2\text{--}0.5$ ;  $P_i < 0.5$ ), consistent with docking results indicating strong receptor affinity.

ADMET predictions using SwissADME and ProTox 3.0 revealed that only EGCG and chlorogenic acid met Lipinski’s Rule of Five, suggesting better drug-likeness and bioavailability (Figure 5). Theaflavin derivatives violated the rule due to high molecular weight and hydrogen bonding. Reference drugs showed high human intestinal absorption (HIA) and blood–brain barrier (BBB) permeability, while tea polyphenols displayed lower values. Nevertheless, all ligands were predicted to be non-carcinogenic and of low toxicity (classes IV–V).

Despite favorable docking and PASS predictions, the black tea compounds exhibited limited systemic bioavailability and poor blood–brain barrier (BBB) permeability, which may restrict their efficacy within the central nervous system (CNS). Nevertheless, other studies have reported that

theaflavin, one of the major constituents of black tea, not only accelerates functional recovery of the sciatic nerve but also effectively mitigates oxidative stress<sup>51</sup>. These limitations are typical of polyphenolic compounds and may be addressed through nanoformulation or structural modification to enhance brain delivery<sup>52</sup>. Nanoformulation approaches, in particular, offer promising strategies to overcome these pharmacokinetic constraints. Encapsulation of bioactive compounds into nanocarriers such as lipid-based nanoparticles, polymeric nanoparticles, nanoemulsions, or solid lipid nanoparticles has been shown to significantly improve solubility, stability, and resistance to gastrointestinal degradation.

Moreover, nanocarriers can be engineered with surface modifications (e.g., PEGylation, ligand-functionalization targeting transferrin or lactoferrin receptors) to facilitate transport across the BBB via receptor-mediated transcytosis<sup>53</sup>. These systems not only enhance bioavailability but may also prolong circulation time and enable controlled release, thereby increasing the likelihood of achieving therapeutically relevant concentrations in the brain. Consequently, integrating nanoformulation strategies may substantially improve the translational potential of black tea polyphenols as neuroprotective agents for Alzheimer's disease<sup>54</sup>.



**Figure 5.** Visualization of bioavailability radar results generated using SwissADME for (A) Donepezil, (B) Rivastigmine, (C) Epigallocatechin gallate, (D) Theaflavin-3-O-gallate, and (E) Chlorogenic Acid.

**Table 2.** HOMO-LUMO energy values and other properties.

Ligands	Homo (eV)	Lumo (eV)	Energy gap (eV)	I (eV)	A (eV)	$\mu$ (eV)	$\chi$ (eV)	$\eta$ (eV)	S (eV)	$\omega$ (eV)
Donepezil	-5.72	-1.09	4.63	5.72	1.09	-3.40	3.40	2.32	0.22	2.50
Rivastigmine	-5.75	0.13	5.88	5.75	-0.13	-2.81	2.81	2.94	0.17	1.35
Epigallocatechin gallate	-5.53	-1.11	4.42	5.53	1.11	-3.32	3.32	2.21	0.23	2.50
Chlorogenic Acid	-6.05	-2.15	3.90	6.05	2.15	-4.10	4.10	1.95	0.26	4.31

To further elucidate their electronic characteristics, frontier molecular orbital (FMO) analysis was performed using density functional theory (DFT). This approach provides insight into molecular reactivity and stability by evaluating the energy gap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular

orbital (LUMO) (37). The HOMO energy reflects the electron-donating capacity, while the LUMO energy represents the electron-accepting ability<sup>55</sup>. Among the tested ligands, EGCG exhibited the highest HOMO value (-5.53 eV), indicating superior electron-donating potential. Conversely, chlorogenic acid had the lowest HOMO (-6.05 eV) and LUMO (-2.15 eV)

values, suggesting high molecular stability and the strongest electron-accepting capacity (Table 2). These findings support the observed docking interactions and highlight EGCG and chlorogenic acid as the most promising candidates for further development as anti-Alzheimer’s agents. Overall, EGCG and chlorogenic acid showed the most promising pharmacological profiles among the tested black tea compounds, indicating their potential as natural AChE inhibitors and anti-Alzheimer’s agents for further *in vitro* and *in vivo* exploration.

**Acetylcholinesterase (AChE) Enzyme Inhibition**

The inhibitory activity of the black tea water extract originating from Bogor, Indonesia, was evaluated to validate the *in silico* predictions. The


water extract exhibited concentration-dependent inhibition of AChE activity. The Bogor black tea extract showed strong inhibitory effects, with an IC<sub>50</sub> value of 44.85 ± 1.48 µg/mL (Table 3; Figure 6). When compared with Donepezil (Table 4, Figure 7), a standard AChE inhibitor and commercially used drug for Alzheimer’s disease, the IC<sub>50</sub> value of the Bogor black tea extract was considerably higher, indicating that Donepezil retains a stronger inhibitory potency. However, relative to other studies, the Bogor black tea extract demonstrated a more favorable AChE inhibitory profile, with a lower IC<sub>50</sub> than that reported by Okello et al. (2004)<sup>57</sup>, which was 60 µg/mL, and slightly higher than the IC<sub>50</sub> value reported by Piyasena et al. (2025)<sup>58</sup>, which was 36.75 µg/mL.

**Table 3.** IC<sub>50</sub> value of black tea from Bogor, Indonesia.


Black Tea	Concentration (µg/mL)								IC <sub>50</sub> (µg/mL)	Mean of IC <sub>50</sub>	SD
	0,1	1	5	10	20	30	40	50			
Replicate 1	1,58	6,00	11,69	16,75	30,96	33,18	50,55	52,09	43,81	44,85	1,48
Replicate 2	0,64	5,09	11,45	16,85	30,21	32,43	50,55	52,49	45,90		

**Table 4.** IC<sub>50</sub> value of Donepezil as a reference AChE inhibitor.

Donepezil HCl	Concentration (µg/mL)						IC <sub>50</sub> (µg/mL)	Mean of IC <sub>50</sub>	SD
	0,00625	0,0125	0,025	0,05	0,1	0,2			
Replicate 1	1,1834	24,4576	44,9704	78,5010	87,9684	96,4286	0,0291	0,0289	0,0003
Replicate 2	1,9646	23,9686	45,5796	78,9784	88,4086	97,2332	0,0287		



**Figure 6.** Inhibition curve of AChE by black tea water extract from Bogor. Red squares represent the first replicate, and blue circles represent the second replicate.



**Figure 7.** Inhibition curve of AChE by Donepezil as positive control (standard AChE inhibitor). Red squares represent the first replicate, and blue circles represent the second replicate.

The *in vitro* assay results supported the computational findings. These data confirm the anti-Alzheimer's potential of Indonesian black tea, particularly through the stable and reactive characteristics of EGCG and chlorogenic acid as indicated by DFT energy-gap (eV) analysis. The affinity and stability of EGCG, one of the major constituents of black tea, toward AChE are also consistent with the findings of Samanta et al. (2022), who reported an AChE inhibitory  $IC_{50}$  value of  $30.99 \pm 1.5 \mu\text{g/mL}$ . Using this integrated approach, the study effectively identified candidate compounds with potential anti-Alzheimer's activity, highlighted their interactions within the AChE active-site gorge, and reinforced their relevance as prospective therapeutic agents.

#### 4. CONCLUSIONS

Our *in silico* analyses identified several polyphenolic compounds from Indonesian black tea with strong anti-Alzheimer's potential through acetylcholinesterase (AChE) inhibition. Epigallocatechin gallate exhibited the most favorable binding affinity ( $\Delta G_{bind} = -12.2740 \text{ kcal/mol}$ ), followed by theaflavin derivatives and chlorogenic acid, all of which interacted effectively within the AChE active-site gorge. These compounds also demonstrated favorable PASS predictions and toxicity profiles, although their bioavailability remained limited. DFT analysis revealed lower energy gaps compared with reference inhibitors, indicating higher molecular reactivity and greater binding stability. *In vitro* assays supported the computational predictions, with black tea extract from Bogor showing strong AChE inhibitory activity consistent with previous studies, although its inhibition capacity remained lower than that of Donepezil. Overall, these findings

highlight Indonesian black tea as a promising natural source of AChE inhibitors for Alzheimer's therapy. Future research should prioritize strategies to improve the bioavailability of these compounds.

#### ACKNOWLEDGMENTS

We authors gratefully acknowledge the support of the BIMA – Ministry of Higher Education, Science, and Technology of the Republic of Indonesia through the Fundamental Research Grant (Penelitian Fundamental Reguler). This research was funded by the 2025 BIMA – Ministry of Higher Education, Science, and Technology of the Republic of Indonesia grant for the Fundamental Research Grant (Penelitian Fundamental Reguler) scheme with contract number: 006/C3/DT.05.00/PL/2025.

#### REFERENCES

1. Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, Jaghama W, Karaman D, Karaman R. Promising Natural Remedies for Alzheimer's Disease Therapy. *Molecules.Multidisciplinary Digital Publishing Institute (MDPI)*. 2025;30(4). doi:10.3390/molecules30040922
2. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt, L, Cummings JL, Vergallo A. The Amyloid- $\beta$  Pathway in Alzheimer's Disease. *Mol Psychiatry*. 2021;26(10):5481-5503. doi:10.1038/s41380-021-01249-0
3. Pagano K, Tomaselli S, Molinari H, Ragona L. Natural Compounds as Inhibitors of A $\beta$  Peptide Aggregation: Chemical Requirements and Molecular Mechanisms. *Front*

- Neurosci.Frontiers Media S.A.* 2020;14. doi:10.3389/fnins.2020.619667
4. Nogara PA, Saraiva R de A, Caeran Bueno D, Dalla Corte CL. Virtual Screening of Acetylcholinesterase Inhibitors Using the Lipinski's Rule of Five and ZINC Databank. *Biomed Res Int.* 2015;2015:1-8. doi:10.1155/2015/870389
  5. Kocahan S, Doğan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. *Clinical Psychopharmacology and Neuroscience.* 2017;15(1):1-8. doi:10.9758/cpn.2017.15.1.1
  6. Stanciu GD, Luca A, Rusu RN, Bild V, Beschea Chiriac SL, Solcan C, Bild W, Carmen Ababei D. Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement. *Biomolecules.* 2019;10(1):40. doi:10.3390/biom10010040
  7. Darvesh S. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease. *Curr Alzheimer Res.* 2016;13(10):1173-1177. doi:10.2174/1567205013666160404120542
  8. Moreira NC dos S, Lima JEB de F, Marchiori MF, Carvalho I, Sakamoto-Hojo ET. Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives. *J Alzheimers Dis Rep.* 2022;6(1):177-193. doi:10.3233/ADR-210061
  9. Alzheimer's Disease International. *World Alzheimer Report 2023 Reducing Dementia Risk: Never Too Early, Never Too Late.*; 2023. Accessed November 26, 2024. <https://www.alzint.org/u/World-Alzheimer-Report-2023.pdf>
  10. KEMENKES [Kementerian Kesehatan Indonesia]. Demensia.
  11. Alzheimer's Association Report. 2025 Alzheimer's disease facts and figures. *Alzheimer's & Dementia.* 2025;21(4). doi:10.1002/alz.70235
  12. Soto C, Kindy MS, Baumann M, Frangione B. *Inhibition of Alzheimer's Amyloidosis by Peptides That Prevent Beta-Sheet Conformation.* Vol 226.; 1996.
  13. Rezai-Zadeh K, Arendash GW, Hou H, Frank F, Jensen M, Runfeldt M, Shytle RD, Tan J. Green tea epigallocatechin gallate (EGCG) reduces  $\beta$ -amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. *Brain Res.* 2008;1214:177-187. doi:10.1016/j.brainres.2008.02.107
  14. Dhouafli Z, Cuanalo-Contreras K, Hayouni EA, Mays CE, Soto C, Moreno-Gonzalez I. Inhibition of protein misfolding and aggregation by natural phenolic compounds. *Cellular and Molecular Life Sciences.Birkhauser Verlag AG.* 2018;75(19):3521-3538. doi:10.1007/s00018-018-2872-2
  15. Ma L, Yang C, Zheng J, Chen Y, Xiao Y, Huang K. Non-polyphenolic natural inhibitors of amyloid aggregation. *Eur J Med Chem.Elsevier Masson SAS.* 2020;192. doi:10.1016/j.ejmech.2020.112197
  16. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies. *Signal Transduct Target Ther.* 2024;9(1):211. doi:10.1038/s41392-024-01911-3
  17. Lou YH, Wang JS, Dong G, Guo PP, Wei DD, Xie SS, Yang MH. The acute hepatotoxicity of tacrine explained by <sup>1</sup>H NMR based metabolomic profiling. *Toxicol Res (Camb).* 2015;4(6):1465-1478. doi:10.1039/C5TX00096C
  18. Baranowska-wójcik E, Szwajgier D, Winiarska-mieczan A. Regardless of the brewing conditions, various types of tea are a source of acetylcholinesterase inhibitors. *Nutrients.* 2020;12(3). doi:10.3390/nu12030709
  19. Piyasena KGNP, Ranatunga MAB, Napagoda MT, Amarasinghe NR, Abayarathne AAB, Jayasinghe L. Evaluation of antioxidant, acetylcholinesterase, lipase,  $\alpha$ -amylase, xanthine oxidase, and  $\alpha$ -glucosidase enzyme inhibitory activities of Sri Lankan tea cultivars. *Discover Plants.* 2025;2(1). doi:10.1007/s44372-025-00122-6
  20. Dong X, Yang C, Cao S, Gan Y, Sun H, Gong, Y, Yang H, Yin X, Lu Z. Tea consumption and the risk of depression: A meta-analysis of observational studies. *Australian and New Zealand Journal of Psychiatry.* 2015;49(4):334-345. doi:10.1177/0004867414567759
  21. Anandhan A, Tamilselvam K, Radhiga T, Rao S, Essa MM, Manivasagam T. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. *Brain Res.* 2012;1433:104-113. doi:10.1016/j.brainres.2011.11.021
  22. Deb S, Dutta A, Phukan BC, Manivasagam T, Thenmozhi AJ, Bhattacharya P, Paul R, Borah A. Neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson's disease therapeutics.

- Neurochem Int.Elsevier Ltd.* 2019;129. doi:10.1016/j.neuint.2019.104478
23. Samanta T, Chandran KS, Medda N, Banerjee A, Mitra A, De SK, Maiti S. Black tea and its theaflavin derivatives firmly inhibit acetylcholinesterase activity, possible implications in cholinergic neurodegenerative or muscular disorder. Preprint posted online August 3, 2022. doi:10.21203/rs.3.rs-1902799/v1
  24. Ray S, De B, Article R, De B. *Acetylcholinesterase Inhibitory Properties of Black Tea and Its Polyphenolic Components.*; 2012. <https://www.researchgate.net/publication/274706500>
  25. Hasan AEZ, Safithri M, Huda AS, Kurniasih R. In Silico, To Determine The Active Compounds Of Black Tea And Turmeric In Increasing The Activity Of The Enzyme Sod. *Indonesian Journal of Applied Research (IJAR)*. 2022;3(1):32-45. doi:10.30997/ijar.v3i1.187
  26. Safithri M, Faridah N, Ramadani F, Pratama R. Antioxidant activity of ethanol extract and fractions of *Piper crocatum* with Rancimat and cuprac methods. 2022; <https://doi.org/10.1515/tjb-2021-0300>.
  27. Gerlits O, Ho KY, Cheng X, Blumenthal D, Taylor P, Kovalevsky A, Radic Z. A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. *Chem Biol Interact.* 2019;309. doi:10.1016/j.cbi.2019.06.011
  28. Neese F, Wennmohs F, Becker U, Riplinger C. The ORCA quantum chemistry program package. *J Chem Phys.* 2020;152(22). doi:10.1063/5.0004608
  29. Huda AS, Hasan AEZ, Safithri M. Acetylcholinesterase Enzyme Inhibitor and Antioxidant Activities from A Mixture Extracts of Black Tea, Red Betel, Cinnamon and Curcuma. *Curr. Biochem.* 2022. 9(2): 63-72.
  30. Seniya C, Khan GJ, Uchadia K. Identification of Potential Herbal Inhibitor of Acetylcholinesterase Associated Alzheimer's Disorders Using Molecular Docking and Molecular Dynamics Simulation. *Biochem Res Int.* 2014;2014:1-7. doi:10.1155/2014/705451
  31. Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: From 3D structure to function. *Chem Biol Interact.* 2010;187(1-3):10-22. doi:10.1016/j.cbi.2010.01.042
  32. Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ. Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands. *J Med Chem.* 2012;55(22):10282-10286. doi:10.1021/jm300871x
  33. Lu SH, Wu JW, Liu HL, Zhao JH, Liu KT, Chuang CK, Lin HY, Tsai WB, Ho Y. The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies. *J Biomed Sci.* 2011;18(1):8. doi:10.1186/1423-0127-18-8
  34. Saini R, Saxena AK. The Structural Hybrids of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease: A Review. *Alzheimer's & Neurodegenerative Diseases.* 2018;4(1):1-25. doi:10.24966/AND-9608/100015
  35. Dallakyan S, Olson AJ. Small-Molecule Library Screening by Docking with PyRx. In: 2015:243-250. doi:10.1007/978-1-4939-2269-7\_19
  36. Atanasova M, Yordanov N, Dimitrov I, Berkov S, Doytchinova I. Molecular Docking Study on Galantamine Derivatives as Cholinesterase Inhibitors. *Mol Inform.* 2015;34(6-7):394-403. doi:10.1002/minf.201400145
  37. Doytchinova I, Atanasova M, Valkova I, Valkova I, Starvrakov G, Philipova I, Zhivkova Z, Zheleva-Dimitrova D, Konstantinov S, Dimitrov I. Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database. *J Enzyme Inhib Med Chem.* 2018;33(1):768-776. doi:10.1080/14756366.2018.1458031
  38. Wang W, Le T, Wang W, Yu L, Yang L, Jiang H. Effects of Key Components on the Antioxidant Activity of Black Tea. *Foods.* 2023;12(16):3134. doi:10.3390/foods12163134
  39. Luo Q, Luo L, Zhao J, Wang Y, Luo H. Biological potential and mechanisms of Tea's bioactive compounds: An Updated review. *J Adv Res.Elsevier B.V.* 2024;65:345-363. doi:10.1016/j.jare.2023.12.004
  40. Tandale AT, Nayak BB, Xavier KAM, Devangre AA, Gore SB, Balange AK. Phenolic Compounds and Bioactive Properties of Black Tea Powder. *Indian J Anim Res.* 2024;58(2):342-346. doi:10.18805/IJAR.B-4849
  41. Salimikia I, Aminnezhad S, Maghsoudloo M, Mirzania F. Micro Nano Bio Aspects Anti-neurodegenerative, anticancer, anti-inflammatory, and antiobesity activities of theaflavin and its derivatives. *Micro Nano Bio Aspects.* 2023;2023(4):8-16. doi:10.22034/mnba.2023.413015.1044
  42. Lee MK, Kim HW, Lee SH, Kim YJ, Asamenew G, Choi J, Lee JW, Jung HA, Yoo SM, Kim JB. Characterization of catechins,

- theaflavins, and flavonols by leaf processing step in green and black teas (*Camellia sinensis*) using UPLC-DAD-QToF/MS. *European Food Research and Technology*. 2019;245(5):997-1010. doi:10.1007/s00217-018-3201-6
43. Sato J, Tomita A, Sonoda T, Miyamoto T. Theaflavin and its derivatives exert antibacterial action against *Bacillus coagulans* through adsorption to cell surface phospholipids. *J Appl Microbiol*. 2022;133(3):1781-1790. doi:10.1111/jam.15690
  44. Gargi S, Nilanjan S, Moutusi N, Subhasis M. Bioactive components of tea. *Archive of Food and Nutritional Science*. 2020;4(1):001-009. doi:10.29328/journal.afns.1001020
  45. Li R, Huang YG, Fang D, Le WD. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. *J Neurosci Res*. 2004;78(5):723-731. doi:10.1002/jnr.20315
  46. Sharma N, Phan HT, Chikae M, Takamura Y, Azo-Oussou AF, Vestergaard MC. Black tea polyphenol theaflavin as promising antioxidant and potential copper chelator. *J Sci Food Agric*. 2020;100(7):3126-3135. doi:10.1002/jsfa.10347
  47. Kim CY, Lee C, Park GH, Jang JH. Neuroprotective effect of epigallocatechin gallate against  $\beta$ -amyloid-induced oxidative and nitrosative cell death via augmentation of antioxidant defense capacity. *Arch Pharm Res*. 2009;32(6):869-881. doi:10.1007/s12272-009-1609-z
  48. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. *Nat Struct Mol Biol*. 2008;15(6):558-566. doi:10.1038/nsmb.1437
  49. Herges K, Millward JM, Hentschel N, Infante-Duarte C, Aktas O, Zipp F. Neuroprotective effect of combination therapy of Glatiramer acetate and epigallocatechin gallate in neuroinflammation. *PLoS One*. 2011;6(10). doi:10.1371/journal.pone.0025456
  50. Palhano FL, Lee J, Grimster NP, Kelly JW. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. *J Am Chem Soc*. 2013;135(20):7503-7510. doi:10.1021/ja3115696
  51. Ahmad A, Nosheen F, Arshad MU, Saeed F, Afzaal M, Islam F, Imran A, Noreen R, Ali YA, Shah MA. Isolation and antioxidant characterization of theaflavin for neuroprotective effect in mice model. *Food Sci Nutr*. 2023;11:3485-3496.
  52. Pardridge WM. Drug transport across the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*. 2012;32(11):1959-1972. doi:10.1038/jcbfm.2012.126
  53. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. *Signal Transduct Target Ther. Springer Nature*. 2023;8(1). doi:10.1038/s41392-023-01481-w
  54. Li X, Smid SD, Lin J, Gong Z, Chen S, You F, Zhang Y, Hao Z, Lin H, Yu X. Neuroprotective and anti-amyloid  $\beta$  effect and main chemical profiles of white tea: Comparison against green, oolong and Black tea. *Molecules*. 2019;24(10). doi:10.3390/molecules24101926
  55. Yu J, Su NQ, Yang W. Describing Chemical Reactivity with Frontier Molecular Orbitals. *JACS Au*. 2022;2(6):1383-1394. doi:10.1021/jacsau.2c00085
  56. Okello E.J, Savelev SU, Perry EK. *In vitro* Anti- $\beta$ -secretase and Dual Anti cholinesterase Activities of *Camellia sinensis* L. (tea) Relevant to Treatment of Dementia. *Phytother. Res*. 18, 624-627 (2004)
  57. Piyasena KGNP, Ranatunga MAB, Napagoda MT, Amarasinghe NR, Abarayathne AAB, Jayasinghe L. Evaluation of antioxidant, acetylcholinesterase, lipase,  $\alpha$ -amylase, xanthine oxidase, and  $\alpha$ -glucosidase enzyme inhibitory activities of Sri Lankan tea cultivars. *Discover Plants* (2025) 2:49